Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Trial Profile

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2018

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Cognition disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms A4
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Sep 2018 Planned End Date changed from 1 Jul 2022 to 22 Jul 2022.
    • 11 Sep 2018 Planned primary completion date changed from 1 Jul 2022 to 22 Jul 2022.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top